Outsourcing

Chris Spivey is director of Industry Relations and Strategic Partnership, MJH Life Sciences.

Videos

Marianna Tcherpakov, PhD, director of Business Development, CMC Services, at Frontage Laboratories, spoke on the CDMO’s role in tackling complex technical challenges to enable startup biotechs solve scale up problems.

BIO 2024: CDMOs Focus on Complex Technical Challenges to Boost Startup Biotechs

Articles

Emerging therapies, patient-centric medicines, and the ever-changing world of bio/pharmaceuticals complicate technology transfer.

Tech Transfer in the New World of New Modalities

Ahmed Youssef, senior manager, USP Process Development at Ascend, provides insight on tech transfer when developing and manufacturing emerging therapies and new modalities.

Tech Transfer Considerations

Feliza Mirasol is the science editor for 

CPHI Milan 2024: Industry Trends Impacting Oral Solid Dose Formulation

According to the annual survey, four of the five biggest biologics capacity holders in 2028 will comprise CMOs, which are expected to have 45% of all CMO capacity in Asia.

CMOs and Hybrid Companies Predicted to Hold 54% of Biologics Capacity in 2028, According to CPHI Annual Survey

The nanofiber microcarriers are the first of their kind for manufacturing viral vectors used in gene therapy production, according to Cellevate.

Cellevate Plans Pre-Launch of First Nanofiber Microcarriers for Viral Vector Manufacturing at CPHI Milan

As part of a range of sustainable products and services that SGD Pharma plans to showcase at CPHI Milan, the company will introduce its siliconized molded glass vials.

SGD Pharma to Introduce Siliconized Molded Glass Vials at CPHI Milan to Showcase Sustainable Packaging

According to the survey results, 49% of industry respondents are “highly positive” on the contract services sector seeing growth over the next 18 months.

Results from CPHI Milan Survey Find No Favor Among Industry for BIOSECURE Act While Predicting Faster Growth for CDMOs in 2025

Lonza signed a long-term supply agreement to manufacture CASGEVY (exagamglogene autotemcel) for Vertex at its facility in Geleen, the Netherlands, and plans to expand manufacturing to Portsmouth, NH, in the United States.

Lonza and Vertex Enter Commercial Supply Agreement for CASGEVY, the Sickle Cell Disease Gene-Edited Cell Therapy

Patrick Lavery is an Editor for the MJH Life Sciences brands 

. Previously at MJH, he filled the same role for 

The critical APIs that this funding will contribute to are used in the treatment of asthma, diabetes, and anxiety disorders.

Contract Manufacturing Services